Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altamira Therapeutics Ltd
(NQ:
CYTO
)
0.9553
-0.0291 (-2.96%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Altamira Therapeutics Ltd
< Previous
1
2
3
4
Next >
Altamira Therapeutics to Participate at RNA Leaders USA Congress
October 13, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia
October 03, 2022
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal
July 28, 2022
•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of JMJD3 gene remarkably mitigated severity of joint...
From
Altamira Therapeutics Ltd
Via
GlobeNewswire
Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal
July 12, 2022
HAMILTON, BERMUDA / ACCESSWIRE / July 12, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical...
From
Altamira Therapeutics Ltd.
Via
AccessWire
Topics
Death
Exposures
Death
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan
June 29, 2022
Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis
June 27, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 27, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
Product Safety
Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19
June 23, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo
June 13, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 13, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics Ltd.
Via
AccessWire
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements
June 09, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray
June 08, 2022
HAMILTON, BERMUDA / ACCESSWIRE / June 8, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia
May 31, 2022
HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray
May 23, 2022
HAMILTON, BERMUDA / ACCESSWIRE / May 23, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Exposures
Product Safety
Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study
May 20, 2022
Company's drug-free nasal spray demonstrated a statistically significant reduction of nasal symptoms vs. untreated controls as well as good tolerability and safety
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference
May 19, 2022
HAMILTON, BERMUDA / ACCESSWIRE / May 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Therapeutics Issues Shareholder Letter
May 18, 2022
Highlights Company's progress to becoming a pure-play RNA business and tech strategy and penetrate the multi-billion TAM HAMILTON, BERMUDA / ACCESSWIRE / May 18, 2022 / Altamira Therapeutics Ltd....
From
Altamira Therapeutics
Via
AccessWire
Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia
May 05, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19
April 19, 2022
HAMILTON, BERMUDA / ACCESSWIRE / April 19, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results
April 12, 2022
- Management will host an investor conference call today, Tuesday, at 8 a.m. Eastern. - Company pivots towards RNA therapeutics and its OligoPhore™ / SemaPhore™ platform for extrahepatic RNA deliver -...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant
April 11, 2022
Study Confirms in vitro Efficacy / Safety of Bentrio(TM) for Delta Variant - Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET
April 04, 2022
HAMILTON, BERMUDA / ACCESSWIRE / April 4, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it...
From
Altamira Therapeutics
Via
AccessWire
Topics
Earnings
Exposures
Financial
Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio
March 15, 2022
HAMILTON, BERMUDA / ACCESSWIRE / March 15, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
March 11, 2022
HAMILTON, BERMUDA / ACCESSWIRE / March 11, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19
March 09, 2022
HAMILTON, BERMUDA / ACCESSWIRE / March 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Exposures
COVID-19
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets
March 04, 2022
- Nuance Pharma to develop and commercialize Bentrio™ nasal spray in Chinese Mainland, Hong Kong, Macau and South Korea - Altamira to receive up to $23.5 million in upfront and milestone payments...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo
February 14, 2022
- 75 patients randomized in Part B of study to receive either intranasal betahistine or placebo - Top-line results from the trial expected to be announced in Q2-2022 HAMILTON, BERMUDA / ACCESSWIRE /...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets
February 09, 2022
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
February 07, 2022
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Establishes OTC Consumer Health Business Unit
February 04, 2022
- Dedicated unit to support Altamira's activities in consumer health products - OTC Consumer Health to be led by experienced marketing strategist, Jean Lachance HAMILTON, BERMUDA / ACCESSWIRE /...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia
January 21, 2022
HAMILTON, BERMUDA / ACCESSWIRE / January 21, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection...
From
Altamira Therapeutics
Via
AccessWire
Altamira Therapeutics Provides Update on RNA Therapeutics Program
January 13, 2022
- Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeutics - Receipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory...
From
Altamira Therapeutics
Via
AccessWire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.